Ian E. Krop, MD, PhD

Ian E. Krop, MD, PhD, is the director of the Clinical Trials Office, as well as chief clinical research officer and associate director of Clinical Sciences at Yale Cancer Center.

Articles

Dr Krop on Zanidatamab Plus Evorpacept in HER2+ Metastatic Breast Cancer

February 7th 2025

Ian Krop, MD, PhD, discusses zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer.

Dr Krop on the Efficacy and Tolerability of SHR-A1811 in Advanced HER2+ Breast Cancer

January 20th 2025

Ian Krop, MD, PhD, discusses SHR-A1811, a third-generation antibody-drug conjugate for HER2-positive breast cancer.

Dr Krop on Age-Related Survival Outcomes With T-DXd in HER2+ Breast Cancer

July 21st 2023

Ian E. Krop, MD, PhD, discusses the use of fam-trastuzumab deruxtecan-nxki across age groups in the DESTINY Breast trials in patients with HER2-positive metastatic breast cancer.

Trastuzumab Deruxtecan in the Neoadjuvant Setting

February 8th 2023

Closing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.

The Emerging State of HER2-low Breast Cancer

February 1st 2023

Dr Geyer and Dr Krop discuss key data and the evolving standard of care for patients with HER2-low breast cancer.

Unmet Needs for Patients with HER2+ Breast Cancer with Brain Metastases

February 1st 2023

Breast cancer experts exchange thoughts on the treatment of HER2+ breast cancer with CNS involvement, particularly the use of trastuzumab deruxtecan in this subset of patients.

Key Takeaways from Clinical Trials of Trastuzumab Deruxtecan in Different Populations

January 25th 2023

Dr Krop leads a discussion of results from the DESTINY-Breast02 and DESTINY-Breast03 studies concerning the use of trastuzumab deruxtecan in patients with metastatic breast cancer.

Recent Updates for the Advanced HR+ Breast Cancer Setting

January 25th 2023

Charles E. Geyer, MD and Ian E. Krop, MD, PhD touch on recent advances in the metastatic HR+ breast cancer setting and evaluate PROTAC estrogen receptor (ER) degraders compared with other ER modulators.

Clinical Implications of SERENA-2 Trial Data

January 18th 2023

Conversation centered around the clinical implications of recently presented data from the randomized, multi-dose phase II SERENA-2 trial.

Novel Agents in the Adjuvant Setting: PARP Inhibitors

January 18th 2023

Dr Geyer and Dr Krop explore data from the OlympiA phase III trial of adjuvant olaparib in patients with variants in BRCA1/2.

Updates in the Treatment of Early-stage HR+ Breast Cancer

January 11th 2023

Two breast cancer experts review updates from the SOFT and TAILORx trials and discuss racial disparities in breast cancer treatment and clinical trials.

The Evolution of the Breast Cancer Treatment Landscape

January 11th 2023

Charles E. Geyer, MD and Ian E. Krop, MD, PhD provide an overview of the current breast cancer treatment landscape, with a focus on the management of patients with ER+/HER2- metastatic breast cancer.

Dr. Krop on Evaluating De-Escalated Treatment Strategies in HER2+ Breast Cancer

January 31st 2022

Ian E. Krop, MD, PhD, discusses the need to evaluate de-escalated treatment strategies in HER2-positive breast cancer.

Dr. Krop Discusses Progress Made in Metastatic HER2+ Breast Cancer

January 12th 2022

Ian E. Krop, MD, PhD, discusses progress made in 2021 in the management of HER2-positive breast cancer.

Dr. Krop on the Role of Neratinib as Extended Adjuvant Therapy in HR+/HER2+ Breast Cancer

November 9th 2020

Ian E. Krop, MD, PhD, discusses the role of neratinib as extended adjuvant therapy in high-risk, hormone receptor–positive, HER2-positive breast cancer.

Dr. Krop on the Impact of Recent Advances in Breast Cancer

August 30th 2018

Ian E. Krop, MD, PhD, chief, Breast Oncology, Susan F. Smith Center for Women’s Cancers, clinical research director, Breast Oncology Center, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the impact of recent advances in breast cancer.

Krop Takes Stock of Targeted Therapy Advances in HER2-Positive Breast Cancer

May 20th 2015

As the field evolves, it is likely that HER2-directed agents will be used to an increasing extent instead of conventional chemotherapy, further reducing toxicity.